Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Purpose To provide an update on recent advances in the management of patients with
multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A …

Disease overview: Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis: The diagnosis requires 10% or more clonal plasma cells on bone …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

The treatment of multiple myeloma has changed dramatically in the past decade. The
increase in the number of active agents has generated numerous possible drug …

Purpose In patients with myeloma, thalidomide significantly improves outcomes but
increases the risk of thromboembolic events. In this randomized, open-label, multicenter …

Complete response (CR) was an uncommon event in elderly myeloma patients until novel
agents were combined with standard oral melphalan-prednisone. This analysis assesses …

Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma
(MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal …

Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people
each year and is the second most common hematologic malignancy. It is part of a spectrum …